CHARLOTTE, N.C.--(BUSINESS WIRE)--Aug 7, 2018--Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC (“Nephcentric”), a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders. The agreement names Tanner as a distributor of ure-Na (Urea 15g) in areas outside of the United States, Canada, and the Middle East where the product is not yet registered. ure-Na (Urea 15g) is a Medical Food for the management of hyponatremia.

The distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turn key global access solutions for the distribution of products from markets of supply to markets of demand.

Maryori Alvarenga, Managing Director of US and Global Director for TannerGAP, commented, “We are excited to work with Nephcentric on a global level to provide ure-NA access to patients in need.”

Caroline Von Scheven, Operations Lead for Nephcentric, added, “We are looking forward to our partnership with Tanner to help expand our reach beyond North America. Our partnership with Tanner will help more patients in need gain access to our cost-effective, evidence-based therapeutic options.”

To obtain additional details about Global Access Programs, please contact a Tanner Pharma representative at +1 704 552 8408 or email general@tannerpharma.com. For Nephcentric product related enquiries, please email nephcentric@tannerpharma.com.

About Tanner Pharma Group

For over 15 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners. Companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programs, and source comparator drugs for clinical trials and bioanalysis. For more information, visit www.tannerpharma.com.

About Nephcentric LLC:

Nephcentric LLC focuses on cost effective, problem solving, needs-based therapeutic options for patients and physicians. Unlike a traditional biopharmaceutical company, which often relies on higher prices in the specialty space, Nephcentric relies on a lower cost, high efficiency model to bring ure-Na and other products to the medical marketplace. For more information, please visit www.nephcentric.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005014/en/

CONTACT: Tanner Pharma Group

Lindsey Stevens, 704-552-8408

lstevens@tannerpharma.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: SUPPLY CHAIN MANAGEMENT HEALTH BIOTECHNOLOGY PHARMACEUTICAL RETAIL

SOURCE: Tanner Pharma Group

Copyright Business Wire 2018.

PUB: 08/07/2018 06:10 AM/DISC: 08/07/2018 06:10 AM

http://www.businesswire.com/news/home/20180807005014/en